Literature DB >> 28318222

Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor.

S Denise Field1, Jacob Arkin1, Jing Li1, Lyn H Jones1.   

Abstract

PF-956980 has been used previously as a JAK3-selective chemical probe in numerous cell-based experiments. Here, we report that not only is PF-956980 a pan-JAK ATP-competitive inhibitor but it also causes selective reduction of endogenous JAK2 and JAK3 protein levels in human primary immune cells (in a time-dependent manner), leaving the other JAK family members (JAK1 and TYK2) unchanged. We found that PF-956980 selectively downregulated JAK2 and JAK3 mRNA, corresponding to changes observed at the protein level. This work highlights therapeutic opportunities for the development of pharmacological inhibitors that also modulate the expression of their cognate binding proteins.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28318222     DOI: 10.1021/acschembio.7b00116

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  7 in total

1.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

Authors:  George M Burslem; Blake E Smith; Ashton C Lai; Saul Jaime-Figueroa; Daniel C McQuaid; Daniel P Bondeson; Momar Toure; Hanqing Dong; Yimin Qian; Jing Wang; Andrew P Crew; John Hines; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

2.  Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

Authors:  Daniel P Bondeson; Blake E Smith; George M Burslem; Alexandru D Buhimschi; John Hines; Saul Jaime-Figueroa; Jing Wang; Brian D Hamman; Alexey Ishchenko; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

3.  ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation.

Authors:  Qi Zhang; Jingyu Zhang; Evripidis Gavathiotis
Journal:  ACS Chem Biol       Date:  2018-05-02       Impact factor: 5.100

Review 4.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 5.  Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.

Authors:  Chao Wang; Yujing Zhang; Lingyu Shi; Shanbo Yang; Jing Chang; Yingjie Zhong; Qian Li; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 6.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.

Authors:  Milka Kostic; Lyn H Jones
Journal:  Trends Pharmacol Sci       Date:  2020-03-26       Impact factor: 14.819

Review 7.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.